Product Name | YVLDHLIVV |
Product Quantity | 4mg |
Catalog Number | LT8265 |
Category | EBV_BRLF1 |
Sequence | YVLDHLIVV |
Purity | >95% |
Product Description | The YVLDHLIVV peptide is derived from the BRLF1 protein of Epstein-Barr virus (EBV), an immediate-early lytic cycle protein. This epitope is presented by HLA-A*02:01 and recognized by CD8+ T cells. It is used in studies of EBV-specific immune responses, vaccine development, and understanding the role of T cells in controlling EBV infections. |
Scientific Background | YVLDHLIVV is a 9-residue synthetic peptide with the sequence Tyr-Val-Leu-Asp-His-Leu-Ile-Val-Val. The sequence has a relatively high hydrophobic-residue fraction that can influence aqueous solubility and surface adsorption. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Research Applications | - LC-MS/HPLC analytical method development
- sequence-specific assay controls
|
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
